 |
Panorama of Celltrion headquarters. (Photo=Celltrion) |
[Alpha Biz= Reporter Kim Sangjin] Daol Securities predicts that Celltrion will achieve strong performance following the launch of its first new drug, 'ZYMFENTRA,' in the US market in the second half of this year, significantly increasing its estimated annual sales.
In its report released on the 28th, Daol Securities estimated Celltrion's consolidated annual sales for this year to be 3.5594 trillion won, up 63.5% from the same period last year. The annual operating profit for this year is estimated to be 670 billion won, a 2.9% increase from the previous year.
Analysis suggests that with the full reflection of ZYMFENTRA sales, which obtained final sales approval in the US market last year, performance is expected to improve. The researcher also raised Celltrion's target stock price by about 14%, from the previous 210,000 won to 240,000 won.
Daol Securities explained, "With the full-scale sales of new products such as ZYMFENTRA, Stellara, Jolair, and Aylia, we anticipate a 'high rise after a low start' in performance."
Daol Securities also expects Celltrion to gradually reduce the costs incurred during the merger process. They added, "The temporary increase in costs due to the merger and the impact of the Purchase Price Allocation (PPA) depreciation are expected to decrease as we move into the second half of the year."
Alphabiz Reporter Kim SangJin(letyou@alphabiz.co.kr)
